Abstract
PLATELET aggregation is mediated by at least three distinct mechanisms1,2. The first involves the release of ADP and is inhibited by its conversion to ATP by the combination of creatine phosphate and creatine phosphokinase (CP/CPK). The second is mediated by metabolites of arachidonic acid, particularly thromboxane A2 (TXA2), and is blocked by aspirin or indomethacin, inhibitors of the arachidonate cyclo-oxygenase pathway3. It has been postulated that a third mechanism must exist, as neither CP/CPK nor aspirin, alone or combined, can inhibit aggregation induced by high concentrations of thrombin or the calcium ionophore A23187 (refs 1, 2, 4). Antigenic challenge of IgE-sensitised basophils releases a platelet-activating, factor (PAF), probably a 1-lysophosphatidylcholine5. PAF has a potent action on rabbit6,7 and human8,9 platelet aggregation and release which is independent of the cyclo-oxygenase arachidonate pathways6,10,11. We have also obtained PAF from A23187-stimulated rat peritoneal12 and alveolar (J.B., B. Arnoux and D. Duval, in preparation) macrophages. Moreover, thrombin and ionophore-induced platelet aggregation and the accompanying stimulation of phospholipase A2 (refs 13, 14) are inhibited by the phospholipase inhibitor bromophenacyl bromide (ref. 15 and B.B.V., F. Fouque and M.C., in preparation), suggesting that the third mechanism of platelet aggregation might involve a lipid mediator. These findings prompted us to investigate whether platelets can form and release PAF in experimental conditions in which the ADP and TXA2 pathways are fully blocked. We report here that this is indeed the case, and suggest PAF as a likely candidate for mediating the ‘third pathway’ of platelet aggregation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kinlough-Rathbone, R. L., Packham, M. A., Reimers, H. J., Cazenave, J. P. & Mustard, J. F. J. Lab. clin. Med. 90, 707–719 (1977).
Packham, M. A., Guccione, M. A., Greenberg, J. P., Kinlough-Rathbone, R. L. & Mustard, J. F. Blood 50, 915–926 (1977).
Vargaftig, B. B. & Zirinis, P. Nature new Biol. 244, 144–146 (1973).
Vargaftig, B. B. J. Pharm. Pharmac. 29, 222–228 (1977).
Benveniste, J. Le Couedic, J. P., Polonsky, J. & Tence, M. Nature 269, 170–171 (1977).
Benveniste, J., Henson, P. M. & Cochrane, C. G. J. exp. Med. 136, 1356–1377 (1972).
Benveniste, J. Nature 249, 581–583 (1974).
Benveniste, J. Le Couedic, J. P. & Kamoun, P. Lancet i, 344 (1975).
O'Donnell, M. C., Henson, P. M. & Fiedel, B. A. Immunology 35, 953–958 (1979).
Cazenave, J. P., Benveniste, J. & Mustard, J. F. Fedn Proc. 36, 454 (1977).
Vargaftig, B. B., Lefort, J., Prancan, A. V., Chignard, M. & Benveniste, J. Haemostasis (in the press).
Mencia-Huerta, J. M. & Benveniste, J. Eur. J. Immun. (in the press).
Schoene, N. W. & Iacono, J. M. Fedn Proc. 34, 257 (1975).
Pickett, W. C., Jesse, R. L. & Cohen, P. Biochem. biophys. Acta 486, 209–213 (1977).
Vallee, E. & Delahayes, J. F. Eur. J. Rheum. Inflammation 1, 300–304 (1978).
Ardlie, N. G., Packham, M. A. & Mustard, J. F. Br. J. Haemat. 19, 7–17 (1970).
Bang, N. V., Heidenreich, R. O. & Trygstad, C. W. Ann. N.Y. Acad. Sci. 201, 280 (1972).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
CHIGNARD, M., LE COUEDIC, J., TENCE, M. et al. The role of platelet-activating factor in platelet aggregation. Nature 279, 799–800 (1979). https://doi.org/10.1038/279799a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/279799a0
This article is cited by
-
The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells
Clinical & Experimental Metastasis (2020)
-
Elevated Plasma Platelet Activating Factor, Platelet Activating Factor Acetylhydrolase Levels and Risk of Coronary Heart Disease or Blood Stasis Syndrome of Coronary Heart Disease in Chinese: A Case Control Study
Inflammation (2012)
-
Effects of platelet-activating factor on cardiovascular function, oxygen free radical status, and blood chemistry
International Journal of Angiology (2011)
-
Role of cytokines and platelet-activating factor in inflammatory bowel disease
Diseases of the Colon & Rectum (1996)
-
Ether lipids based on the glyceryl ether skeleton: Present state, future potential
Journal of the American Oil Chemists' Society (1996)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
